NASDAQ · SPRB
Healthcare · Biotechnology
$57.93
Up+$0.22 (+0.38%)
Updated Sep 7, 2026, 4:27 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SPRB closed at $57.93 after 20 trading sessions, up 25.39% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $57.37 | $58.19 | $56.57 | $57.93 | 104.95K |
| Sep 3, 2026 | $59.76 | $60.315 | $57.30 | $57.71 | 116.62K |
| Sep 2, 2026 | $56.52 | $60.13 | $56.52 | $59.67 | 268.14K |
| Sep 1, 2026 | $58.01 | $58.05 | $55.34 | $55.60 | 58.13K |
| Aug 31, 2026 | $60.54 | $60.90 | $57.575 | $58.97 | 44.94K |
| Aug 28, 2026 | $62.115 | $62.98 | $59.895 | $60.78 | 39.96K |
| Aug 27, 2026 | $62.00 | $63.56 | $60.55 | $63.30 | 80.3K |
| Aug 26, 2026 | $64.50 | $64.50 | $60.46 | $61.48 | 91.77K |
| Aug 25, 2026 | $58.82 | $64.15 | $58.00 | $63.40 | 147.3K |
| Aug 24, 2026 | $53.04 | $58.92 | $51.16 | $58.65 | 138.81K |
| Aug 21, 2026 | $52.48 | $53.00 | $49.03 | $51.58 | 62.31K |
| Aug 20, 2026 | $52.83 | $52.89 | $50.50 | $51.985 | 21.64K |
| Aug 19, 2026 | $54.18 | $54.93 | $52.02 | $52.96 | 88.35K |
| Aug 18, 2026 | $51.305 | $53.95 | $50.80 | $52.845 | 71.41K |
| Aug 17, 2026 | $51.57 | $53.60 | $48.92 | $52.92 | 34.8K |
| Aug 14, 2026 | $50.14 | $52.64 | $48.55 | $52.64 | 42.27K |
| Aug 13, 2026 | $47.33 | $51.25 | $47.31 | $49.77 | 50.69K |
| Aug 12, 2026 | $46.95 | $49.00 | $46.26 | $47.07 | 26.25K |
| Aug 11, 2026 | $46.41 | $47.4525 | $46.1078 | $46.41 | 24.25K |
| Aug 10, 2026 | $46.69 | $46.69 | $45.0103 | $46.20 | 35.63K |
The latest Smart Investors Daily articles mentioning SPRB.
SPRB research
Company profile and research snapshot.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Guggenheim | Buy | — |
| Aug 13, 2026 | Citizens | Market Outperform | — |
| Jul 13, 2026 | B. Riley Securities | Buy | — |
| Jun 16, 2026 | Guggenheim | Buy | — |
| Jun 9, 2026 | Jones Trading | Buy | — |
No generated briefing is available yet.
Benzinga · Mar 10, 2026
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $180 to $170.
Benzinga · Mar 10, 2026
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Spruce Biosciences (NASDAQ:SPRB) with a Buy and maintains $200 price target.
Benzinga · Mar 9, 2026
Benzinga · Mar 9, 2026
SPRUCE BIOSCIENCES INC by Spruce Biosciences, Inc. (OTC:SPRB) reported quarterly losses of $(36.25) per share which missed the analyst consensus estimate of $(4.22) by 757.99 percent. This is a 15.2 percent increase over
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SPRB.
